Thursday, 27 October 2016

Microscopic Polyangiitis Global Market Segmentation and Major Players Analysis 2022

The report provides comprehensive information on the therapeutics under development for Microscopic Polyangiitis (MPA), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Microscopic Polyangiitis (MPA) and features dormant and discontinued projects.

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

- The report provides a snapshot of the global therapeutic landscape of Microscopic Polyangiitis (MPA)
- The report reviews pipeline therapeutics for Microscopic Polyangiitis (MPA) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Microscopic Polyangiitis (MPA) therapeutics and enlists all their major and minor projects
- The report assesses Microscopic Polyangiitis (MPA) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Microscopic Polyangiitis (MPA)

Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Microscopic Polyangiitis (MPA)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Microscopic Polyangiitis (MPA) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Microscopic Polyangiitis (MPA) Overview 6
Therapeutics Development 7
Pipeline Products for Microscopic Polyangiitis (MPA) - Overview 7
Microscopic Polyangiitis (MPA) - Therapeutics under Development by Companies 8
Microscopic Polyangiitis (MPA) - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Microscopic Polyangiitis (MPA) - Products under Development by Companies 12
Microscopic Polyangiitis (MPA) - Companies Involved in Therapeutics Development 13
ChemoCentryx, Inc. 13
Coherus BioSciences, Inc. 14
GlaxoSmithKline Plc 15
Panacea Biotec Limited 16
Sandoz International GmbH 17
Teijin Pharma Limited 18
Microscopic Polyangiitis (MPA) - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
belimumab - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
CCX-168 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
immune globulin (human) - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
rituximab biosimilar - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
rituximab biosimilar - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
rituximab biosimilar - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Microscopic Polyangiitis (MPA) - Dormant Projects 44
Microscopic Polyangiitis (MPA) - Product Development Milestones 45
Featured News & Press Releases 45
Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis 45
Jun 03, 2014: ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation in ANCA-Associated Diseases by the FDA 45
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Access Report @                                  

Contact Info:
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)                                                   

Get in touch:

No comments:

Post a Comment